ESMO World Congress on Gastrointestinal Cancer 2017

Oncology Meeting Resources

28 Jun - 01 Jul 2017, Barcelona, Spain

ESMO World GI 2017 square image

The ESMO World Congress on Gastrointestinal Cancer 2017 (World GI) is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts are open access. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Watch the ESMO scientific videos

World GI 2017: Best Abstracts Session on Colorectal Cancer, Speaker: Filippo Pietrantonio

All interviews from the event on the ESMO Channel





Format available

http://oncologypro.esmo.org/Meeting-Resourc...cancer-screening-participation-rates-in-2016

EDIFICE surveys set out to improve insight into the behavior of the French population with regard to participation in cancer screening programs. The colorectal cancer (CRC) screening program has been...

Date: 28 Jun 2017
Presenter: Jean-François Morere
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...s-of-vitamin-E-in-cisplatin-induced-toxicity

Cisplatin is one of highly consumed and effective antitumor agents while its clinical application is accompanied by nephrotoxicity adverse reactions. Also other complication such as ototoxicity and hepatotoxicity are matter of concern.

Date: 28 Jun 2017
Presenter: Bahareh Hakiminia
Resources: Abstract
Topics: Gastrointestinal Cancers, Palliative and Supportive Care, Complications of Treatment

http://oncologypro.esmo.org/Meeting-Resourc...on-in-the-prevention-of-colon-carcinogenesis

Considering cancer as an end stage of a chronic disease process which can be prevented by positive life style and natural medicinal and food materials before the final outcome of invasive and metastatis,...

Date: 28 Jun 2017
Presenter: UJU Iliemene
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ystems-for-mega-scale-gut-microbiome-testing

The Faecal Occult Blood Test (FOBT) is now widely used in colorectal cancer (CRC) screening. Two types of FOBT tests are most commonly used: the guaiac based FOBT test and the immunochemical FOBT (FIT).

Date: 28 Jun 2017
Presenter: Davids Fridmanis
Resources: Abstract
Topics: Gastrointestinal Cancers, Cancer Aetiology, Epidemiology, Prevention

http://oncologypro.esmo.org/Meeting-Resourc...on-carcinogenesis-in-male-albino-wistar-rats

Being Piper nigrum seeds is rich in cancer chemopreventive polyphenols, it was considered necessary to evaluate the preventive effect of dietary inclusion of this seeds at 1%, 2% and 3% on colon...

Date: 28 Jun 2017
Presenter: Sunday Atawodi
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer

http://oncologypro.esmo.org/Meeting-Resourc...fter-neo-adjuvant-treatment-in-rectal-cancer

Neoadjuvant chemo-radiotherapy in rectal cancer patients aims to reduce local recurrence rates following surgery. About 20% of the patients achieve complete pathological response, characterized by...

Date: 28 Jun 2017
Presenter: Liron Berkovich
Resources: Abstract
Topics: Gastrointestinal Cancers, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...midine-based-dCRT-A-single-centre-experience

The CROSS trial has established CP based CRT as standard of care in pre-operative treatment of oesophageal cancer, and this regimen is being increasingly used as a component of dCRT for inoperable eosphageal cancer.

Date: 28 Jun 2017
Presenter: Nicola Warner
Resources: Abstract
Topics: Gastrointestinal Cancers, Oesophageal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...nib-hydrochloride-in-colorectal-cancer-cells

Loss of P53 binding protein 1 (53BP1), which is a key component in DNA damage repair pathways, has been indicated to induce radioresistance of cancer cells. Our previous study found that icotinib...

Date: 28 Jun 2017
Presenter: Tao Zhang
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...therapy-Is-it-an-important-prognostic-factor

Locally advanced esophageal cancers are generally treated with neoadjuvant chemoradiotherapy, followed by surgery in operable candidates. However, even if a patient is diagnosed with operable disease,...

Date: 28 Jun 2017
Presenter: Hyung Kang Sun
Resources: Abstract
Topics: Gastrointestinal Cancers, Oesophageal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...and-BRAF-gene-mutations-in-colorectal-cancer

The detection of RAS (KRAS and NRAS) and BRAF gene mutations has been essential to determine the treatment strategy for metastatic colorectal cancer (CRC). A multiplex kit simultaneously detecting both...

Date: 28 Jun 2017
Presenter: Tomohiro Nishina
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer